According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

Industrial Park in Gajaria upazila of Munshiganj, located about 50 kilometres from Dhaka city along the Dhaka-Chattogram ...

Halo Pharma's transition to a standalone CDMO allows a concentrated focus on drug product services, enhancing technical ...

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...

India’s largest drug-maker Sun Pharmaceutical Industries posted a 16 per cent year-on-year (Y-o-Y) growth in its consolidated ...

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...

Union Budget 2026 | Investor attention is expected to turn to active pharmaceutical ingredient (API) makers, specialty drug ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

The company is eyeing a revenue of Rs 1,000 crore by 2028 and expects its API plant in Navi Mumbai, which was damaged in a fire in 2025, to resume complete operations by March, Nair tells Moneycontrol ...

Halo Pharma - Whippany Halo Pharma will become a stand-alone business as a result of the sale of the Noramco API and associated business to Siegfried. SK Capital Partners have signed a definitive ...

Shares of smallcap Sigachi Industries witnessed profit booking on Thursday after rising nearly 8 percent in early trade following the announcement of a research and development milestone in active ...